Katayoon Kasaian1, Ana-Maria Chindris, Sam M Wiseman, Karen L Mungall, Thomas Zeng, Kane Tse, Jacqueline E Schein, Michael Rivera, Brian M Necela, Jennifer M Kachergus, John D Casler, Andrew J Mungall, Richard A Moore, Marco A Marra, John A Copland, E Aubrey Thompson, Robert C Smallridge, Steven J M Jones. 1. Canada's Michael Smith Genome Sciences Centre (K.K., K.L.M., T.Z., K.T., J.E.S., A.J.M., R.A.M., M.A.M., S.J.M.J.), BC Cancer Agency, Vancouver, V5Z 4S6 Canada; Department of Otorhinolaryngology-Head and Neck Surgery (A.-M.C., J.D.C.), Mayo Clinic, Jacksonville, Florida 32224; Department of Surgery (S.M.W.), St. Paul's Hospital and University of British Columbia, Vancouver, V6Z 1Y6 Canada; Department of Laboratory Medicine and Pathology (M.R.), Mayo Clinic, Rochester, Minnesota 55905; Department of Cancer Biology (B.M.N., J.M.K., J.A.C., E.A.T., R.C.S.), Mayo Clinic, Jacksonville, Florida 32224; Department of Medical Genetics (M.A.M., S.J.M.J.), University of British Columbia, Vancouver, V6T 1Z4 Canada; Department of Medicine, Division of Endocrinology and Metabolism (R.C.S.), Mayo Clinic, Jacksonville, Florida 32224; and Department of Molecular Biology and Biochemistry (S.J.M.J.), Simon Fraser University, Burnaby, V5A 1S6 Canada.
Abstract
CONTEXT AND OBJECTIVE: Oncocytic thyroid carcinoma, also known as Hürthle cell thyroid carcinoma, accounts for only a small percentage of all thyroid cancers. However, this malignancy often presents at an advanced stage and poses unique challenges to patients and clinicians. Surgical resection of the tumor accompanied in some cases by radioactive iodine treatment, radiation, and chemotherapy are the established modes of therapy. Knowledge of the perturbed oncogenic pathways can provide better understanding of the mechanism of disease and thus opportunities for more effective clinical management. DESIGN AND PATIENTS: Initially, two oncocytic thyroid carcinomas and their matched normal tissues were profiled using whole genome sequencing. Subsequently, 72 oncocytic thyroid carcinomas, one cell line, and five Hürthle cell adenomas were examined by targeted sequencing for the presence of mutations in the multiple endocrine neoplasia I (MEN1) gene. RESULTS: Here we report the identification of MEN1 loss-of-function mutations in 4% of patients diagnosed with oncocytic thyroid carcinoma. Whole genome sequence data also revealed large regions of copy number variation encompassing nearly the entire genomes of these tumors. CONCLUSION: Menin, a ubiquitously expressed nuclear protein, is a well-characterized tumor suppressor whose loss is the cause of MEN1 syndrome. Menin is involved in several major cellular pathways such as regulation of transcription, control of cell cycle, apoptosis, and DNA damage repair pathways. Mutations of this gene in a subset of Hürthle cell tumors point to a potential role for this protein and its associated pathways in thyroid tumorigenesis.
CONTEXT AND OBJECTIVE:Oncocytic thyroid carcinoma, also known as Hürthle cell thyroid carcinoma, accounts for only a small percentage of all thyroid cancers. However, this malignancy often presents at an advanced stage and poses unique challenges to patients and clinicians. Surgical resection of the tumor accompanied in some cases by radioactive iodine treatment, radiation, and chemotherapy are the established modes of therapy. Knowledge of the perturbed oncogenic pathways can provide better understanding of the mechanism of disease and thus opportunities for more effective clinical management. DESIGN AND PATIENTS: Initially, two oncocytic thyroid carcinomas and their matched normal tissues were profiled using whole genome sequencing. Subsequently, 72 oncocytic thyroid carcinomas, one cell line, and five Hürthle cell adenomas were examined by targeted sequencing for the presence of mutations in the multiple endocrine neoplasia I (MEN1) gene. RESULTS: Here we report the identification of MEN1 loss-of-function mutations in 4% of patients diagnosed with oncocytic thyroid carcinoma. Whole genome sequence data also revealed large regions of copy number variation encompassing nearly the entire genomes of these tumors. CONCLUSION:Menin, a ubiquitously expressed nuclear protein, is a well-characterized tumor suppressor whose loss is the cause of MEN1 syndrome. Menin is involved in several major cellular pathways such as regulation of transcription, control of cell cycle, apoptosis, and DNA damage repair pathways. Mutations of this gene in a subset of Hürthle cell tumors point to a potential role for this protein and its associated pathways in thyroid tumorigenesis.
Authors: J H Bassett; S A Forbes; A A Pannett; S E Lloyd; P T Christie; C Wooding; B Harding; G M Besser; C R Edwards; J P Monson; J Sampson; J A Wass; M H Wheeler; R V Thakker Journal: Am J Hum Genet Date: 1998-02 Impact factor: 11.025
Authors: M Kyle Cromer; Lee F Starker; Murim Choi; Robert Udelsman; Carol Nelson-Williams; Richard P Lifton; Tobias Carling Journal: J Clin Endocrinol Metab Date: 2012-06-27 Impact factor: 5.958
Authors: Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz Journal: Cancer Discov Date: 2012-05 Impact factor: 39.397
Authors: Simon A Forbes; Nidhi Bindal; Sally Bamford; Charlotte Cole; Chai Yin Kok; David Beare; Mingming Jia; Rebecca Shepherd; Kenric Leung; Andrew Menzies; Jon W Teague; Peter J Campbell; Michael R Stratton; P Andrew Futreal Journal: Nucleic Acids Res Date: 2010-10-15 Impact factor: 16.971
Authors: Willem E Corver; Dina Ruano; Karin Weijers; Wietske C E den Hartog; Merlijn P van Nieuwenhuizen; Noel de Miranda; Ronald van Eijk; Anneke Middeldorp; Ekaterina S Jordanova; Jan Oosting; Ellen Kapiteijn; Guido Hovens; Jan Smit; Tom van Wezel; Hans Morreau Journal: PLoS One Date: 2012-06-01 Impact factor: 3.240
Authors: Raj K Gopal; Kirsten Kübler; Sarah E Calvo; Paz Polak; Dimitri Livitz; Daniel Rosebrock; Peter M Sadow; Braidie Campbell; Samuel E Donovan; Salma Amin; Benjamin J Gigliotti; Zenon Grabarek; Julian M Hess; Chip Stewart; Lior Z Braunstein; Peter F Arndt; Scott Mordecai; Angela R Shih; Frances Chaves; Tiannan Zhan; Carrie C Lubitz; Jiwoong Kim; A John Iafrate; Lori Wirth; Sareh Parangi; Ignaty Leshchiner; Gilbert H Daniels; Vamsi K Mootha; Dora Dias-Santagata; Gad Getz; David G McFadden Journal: Cancer Cell Date: 2018-08-13 Impact factor: 31.743
Authors: O M Capraru; M Decaussin-Petrucci; M O Joly; A Borda; I S Fanfaret; F Borson-Chazot; S Selmi-Ruby Journal: Acta Endocrinol (Buchar) Date: 2017 Apr-Jun Impact factor: 0.877